Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 4 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 60Neoplasms 24Prostatic Neoplasms 21Multiple Myeloma 17Carcinoma, Non-Small-Cell Lung 15Carcinoma, Hepatocellular 15Stomach Neoplasms 11Papillomavirus Infections 11Lung Neoplasms 11Colorectal Neoplasms 10Melanoma 9Pain, Postoperative 7Neoplasm Metastasis 7Leukemia, Myeloid, Acute 7Waldenstrom Macroglobulinemia 6Lymphoma, Non-Hodgkin 6Leiomyoma 6Hematologic Neoplasms 6Brain Neoplasms 6Smoking Cessation 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Polycystic Ovary Syndrome 5Pain 5Lymphoma 5Glioma 5Carcinoma, Renal Cell 5Venous Thromboembolism 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Tobacco Use Disorder 4

Interventions

anlotinib 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Proteinuria × 1 year × Clear all
NCT07358520 2026-01-22

Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients

Fudan University

Phase 4 Not yet recruiting
40 enrolled

Proteinuria

Data powered by HemOnc (CC BY 4.0) Colophon âš¡